ENANTA PHARMACEUTICALS, INC Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
ENANTA PHARMACEUTICALS, INC (ENTA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $12.91 million as of 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-11-19
- 2025-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $12.91M.
- 2024-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $14.55M.
- 2023-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $16.97M.
- 2022-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $14.98M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-09-30 | $12.91M 10-K · filed 2025-11-19 |
| 2024-09-30 | $14.55M 10-K · filed 2025-11-19 |
| 2023-09-30 | $16.97M 10-K · filed 2024-11-27 |
| 2022-09-30 | $14.98M 10-K · filed 2023-11-22 |
| 2021-09-30 | $11.84M 10-K · filed 2022-11-23 |
| 2020-09-30 | $11.07M 10-K · filed 2021-11-24 |
| 2019-09-30 | $9.90M 10-K · filed 2020-11-25 |
| 2018-09-30 | $7.37M 10-K · filed 2019-11-27 |
| 2017-09-30 | $7.90M 10-K · filed 2018-11-29 |
| 2016-09-30 | $4.92M 10-K · filed 2017-12-11 |
| 2015-09-30 | $2.13M 10-K · filed 2016-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |